Tigilanol tiglate is a drug used to treat melanoma, a type of skin cancer. It is a synthetic form of a compound found in the bark of the magnolia tree and is used in combination with other therapies to destroy cancer cells. It works by stimulating the body’s own immune system to attack the cancer cells and prevent their growth and spread. It is available as a topical cream or injection and is usually used in combination with other treatments such as surgery, radiation, or chemotherapy.
Tigilanol tiglate, sold under the brand name Stelfonta, is a medication specifically used to treat canine mast cell tumors (MCTs). Here's a breakdown of its key features:
- Application: It's currently only approved for veterinary use in dogs.
- Function: Tigilanol tiglate works by directly targeting the tumor. It disrupts the function of mitochondria, the cell's power source, leading to tumor cell death (oncolysis) at the injection site. Additionally, it triggers an inflammatory response that further destroys tumor cells and disrupts blood flow to the tumor, hindering its growth.
- Treatment: It's administered via intratumoral injection, meaning it's directly injected into the mast cell tumor.
- Type of MCTs: Stelfonta is approved for non-metastatic MCTs, which are tumors that haven't spread to other parts of the body. It can be used for both cutaneous (skin-based) and subcutaneous (under-the-skin) MCTs in specific locations, typically on a dog's leg.
Here are some additional things to know about tigilanol tiglate:
- Mechanism: It belongs to a class of compounds called phorbol esters, which activate protein kinase C, a signaling molecule involved in cell growth and survival. By disrupting these pathways, it triggers cell death in cancer cells.
- Effectiveness: Studies have shown promising results for treating MCTs in dogs, with high tumor destruction rates.
- Side effects: Injection site reactions like inflammation, pain, and ulceration are common. In some cases, systemic side effects like fever, lethargy, and loss of appetite may occur.
- Important Note: As with any medication, consult your veterinarian before using tigilanol tiglate on your dog. They can determine if it's the right treatment option based on the specific characteristics of your dog's MCT.
Anatomical Therapeutic Chemical Classification
QL - Antineoplastic and immunomodulating agents
QL01 Antineoplastic agents
QL01X - Others antineoplastic agents
QL01XX Other antineoplastic agents
ATC Code
External Links
Tigilanol tiglate